产品说明书
Phenylbutazone
 |
同义名 : | 苯基丁氮酮 ;Butazolidine |
| CAS号 : | 50-33-9 | |
| 货号 : | A208133 | |
| 分子式 : | C19H20N2O2 | |
| 纯度 : | 97% | |
| 分子量 : | 308.37 | |
| MDL号 : | MFCD00005500 | |
| 存储条件： |
粉末 Sealed in dry,Room Temperature 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(340.5 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Phenylbutazone (PB), a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Prostacyclin synthase is even more sensitive to inactivation by the combined PB and H2O2 treatment, with a corresponding half-maximal effect at PB concentrations near 25 mM[3]. However at IC80, phenylbutazone (+134.4%) and flunixin (+29.7%) had greater COX-2 selectivity than at IC50[4]. Phenylbutazone acts by inhibiting the cyclooxygenase enzyme system, which is responsible for synthesis of prostanoids such as PGE2. It markedly reduces prostanoid-dependent swelling, edema, erythema, and hypersensitivity to pain in inflamed tissues. Phenylbutazone is highly bound (greater than 98%) to plasma protein. After i.v. injection, blood levels decline with an elimination half-life of 3-10 h. The plasma kinetics of phenylbutazone may be dose dependent, with the plasma half-life increasing as the drug dosage level increases. Plasma residues of the drug at 24 h after a single i.v. dose of 2g/450 kg average about 0.9 mg/ml, but considerable variation occurs. Under optimal conditions, the bioavailability of oral phenylbutazone is probably in the region of 70%[5]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
3.24mL 0.65mL 0.32mL |
16.21mL 3.24mL 1.62mL |
32.43mL 6.49mL 3.24mL |
| 参考文献 |
|---|